Categories Cancer Treatment
Search Results for Categories Cancer Treatment page 1
Relevance: Medium-High
Most relevant for: People with advanced ovarian, fallopian tube or primary peritoneal cancer
Update: Promising FDA updates in ovarian cancer
This update highlights recent FDA news focused on ovarian cancer, including a new treatment option and two promising investigational drugs that received the FDA’s Breakthrough Therapy designation. These updates may provide more treatment choices for people with ovarian cancer. (posted 3/09/26)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations
Study: Treating advanced breast cancer with ESR1 mutations shows promise
Treatment with the new hormonal drug camizestrant benefited people with certain advanced breast cancers with a biomarker called an ESR1 mutation. People who participated in the SERENA6 study experienced a longer time before their cancer worsened and had a better quality of life than those who received the standard treatment. This study used a blood test to track changes in the cancer to clarify whether treatment worked before symptoms developed. (posted 2/19/26)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic prostate cancer
Update: News from the FDA on metastatic prostate cancer treatment
This update highlights recent FDA approvals and expanded uses for three drugs related to metastatic prostate cancer treatment. These updates affect how prostate cancer may be found and treated, including new options that may allow some men with advanced prostate cancer to delay or avoid chemotherapy. Overall, these updates may provide more choices for people with metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). (posted 2/13/26)
READ MORE ›
Relevance: High
Most relevant for: People diagnosed with cancer who require 5-FU or capecitabine treatment
Guideline: FDA recommends testing to prevent serious side effects from 5-FU and capecitabine chemotherapy
A small number of people treated with the chemotherapy drugs 5-FU (5-fluorouracil) or capecitabine (Xeloda) can have serious or even life-threatening side effects because their body breaks down the drug more slowly than is typical. A genetic test called DPYD testing can help identify people at higher risk for serious side effects before treatment starts. (posted 2/11/26)
READ MORE ›
Relevance: Medium-High
Most relevant for: People who have had or are considering liquid biopsy testing
Topic: What Patients Need to Know About Liquid Biopsies in Cancer Care
Liquid biopsies are tests that look for signs of cancer in blood or other body fluids. These signs can include cancer cells that have broken away from a tumor, pieces of cancer cell DNA and proteins or other biomarkers found in cancer cells. Liquid biopsies can be used to screen for cancer before a cancer diagnosis or guide treatment after a diagnosis. (posted 2/6/26)
READ MORE ›
Relevance: Medium-High
Most relevant for: People who have early-stage triple-negative breast cancer and an inherited mutation in BRCA1 or BRCA2
Study: Treating triple-negative breast cancer in people with inherited BRCA1 or BRCA2 mutations
This review summarizes two studies highlighted during the 2025 San Antonio Breast Cancer Symposium. Both studies focus on targeted therapy and immunotherapy given before surgery to treat early-stage triple-negative breast cancer in people with inherited BRCA1 or BRCA2 mutations. One study evaluated pre-surgery treatment with Zejula and Jemperli; the other study evaluated Lynparza and Imfinzi. (posted 2/3/26)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with a high risk for pancreatic or colon cancer
Study: Early trial of new vaccine shows promise for treating KRAS-mutated pancreatic and colon cancers
A vaccine for treating pancreatic and colon cancers with a biomarker known as a KRAS mutation produced a strong immune response in people at high risk of recurrence in an early clinical trial. This promising vaccine is now being studied in a larger clinical trial. (Posted 12/9/25)
READ MORE ›
Relevance: High
Most relevant for: People with an inherited mutation in ATM, BRCA1, BRCA2, CHEK2, PALB2 or a Lynch syndrome gene who have been diagnosed with breast, colorectal or pancreatic cancer
Study: Cancer patients with certain inherited mutations have cancer outcomes similar to those without inherited mutations
People with an inherited mutation in certain genes, including ATM, CHEK2, PALB2, BRCA or Lynch syndrome genes, have an increased risk of cancer. In this study, researchers wanted to know whether cancer patients with inherited mutations had a different chance of survival than patients without an inherited mutation in these genes. These results showed that, although the risk of cancer is increased, there is no difference in survival after a diagnosis of breast, pancreatic or colorectal cancer with or without these genetic changes. (posted 11/20/25)
READ MORE ›
Relevance: High
Most relevant for: People diagnosed with early colon cancer
Study: Exercise may delay the return of colon cancer and help people live longer
People who participated in a structured exercise program following completed treatment for colon cancer experienced more time without cancer growth and lived longer than those who did not. This study suggests that regular, moderate-intensity exercise can benefit the long-term health of people with early-stage colon cancer. (Posted 11/05/25)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic castration-resistant prostate cancer
Study: Combination treatment for metastatic castration-resistant prostate cancer may be especially effective for people with BRCA1 or BRCA2 mutations
This review summarizes the results of the TALAPRO2 study. It looked at how well the PARP inhibitor Talzenna (talazoparib) works for treating metastatic castration-resistant prostate cancer (mCRPC). Talzenna appears to be most effective for people with BRCA1 or BRCA2 mutations but is also effective for people with certain other mutations. (posted 9/30/25)
READ MORE ›